Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014, New Report Launched

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) - Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.

Scope

• A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) .
• A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA) .
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 103 pages, “Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014” report covered 14 companies - Genzyme Corporation, F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Pfizer Inc., Paratek Pharmaceuticals, Inc., Neurotune AG Trophos SA, Nexgenix Pharmaceuticals, LLC, Genethon Vybion, Inc., California Stem Cell, Inc., OrphageniX, Inc., Retrophin, LLC, Neuro

Inquiry for more information visit:  http://www.marketresearchreports.com/global-markets-direct/spinal-muscular-atrophy-sma-pipeline-review-h1-2014   

Find All Pharma and Healthcare Reports at:- 

http://www.marketresearchreports.com/pharma-healthcare